Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antineoplastic Immune Cell Clear all
Completed Phase 3 Interventional Results available

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

NCT02973789
View directory record Official record
Conditions
Nonsmall Cell Lung Cancer, NSCLC
Interventions
NovoTTF-200T, Immune checkpoint inhibitors or docetaxel
Device · Drug
Lead sponsor
NovoCure GmbH
Industry
Eligibility
22 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
73
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

NCT06287775
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Durvalumab, Echocardiography Test, Iadademstat, Magnetic Resonance Imaging, Multigated Acquisition Scan
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
43
States / cities
Duarte, California • Irvine, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Recruiting Phase 3 Interventional

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245
View directory record Official record
Conditions
Patients With Non-Small Cell Lung Cancer
Interventions
OSE2101, Docetaxel, NGS HLAA2 assay
Drug · Device
Lead sponsor
OSE Immunotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
79
States / cities
Beverly Hills, California • Encino, California • Los Angeles, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Results available

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

NCT03489343
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumor, Lymphoma
Interventions
Sym023
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Sep 30, 2026, 5:13 AM EDT
Terminated Phase 4 Interventional

Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC

NCT05583188
View directory record Official record
Conditions
NSCLC
Interventions
Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Standard of care neoadjuvant therapy, Surgical Resection
Device · Drug · Other
Lead sponsor
Galvanize Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Sep 30, 2026, 5:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

NCT03138161
View directory record Official record
Conditions
Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
Interventions
Trabectedin, Ipilimumab, Nivolumab
Drug
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

NCT02716038
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
MPDL3280A, Carboplatin, Nab-paclitaxel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 30, 2026, 5:13 AM EDT
Completed No phase listed Observational Results available

Vaccine Immune Recovery After Leukemia

NCT05622682
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
Observational only: Serology and flow cytometry for ALL cohort participants, Observational only: Infection rates
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years to 31 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Chicago, Illinois • Grand Rapids, Michigan • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 1Phase 2 Interventional

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

NCT01183949
View directory record Official record
Conditions
Multiple Myeloma
Interventions
AT7519M, Bortezomib
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Sep 30, 2026, 5:13 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

NCT05688280
View directory record Official record
Conditions
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
Interventions
1.0% IP-001 for Injection
Drug
Lead sponsor
Immunophotonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Coral Gables, Florida • Louisville, Kentucky • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 30, 2026, 5:13 AM EDT
Withdrawn No phase listed Observational

Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)

NCT06283238
View directory record Official record
Conditions
GastroEsophageal Cancer
Interventions
Immune checkpoint inhibitor (ICI) or chemotherapy alone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626
View directory record Official record
Conditions
Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions
STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
Drug · Combination Product
Lead sponsor
Marengo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Sacramento, California • Celebration, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Recruiting Phase 1 Interventional

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT03816345
View directory record Official record
Conditions
Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
Interventions
Biospecimen Collection, Cabozantinib, Fluoropyrimidine, Ipilimumab, Nivolumab, Platinum Compound, Platinum Doublet
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
51
States / cities
Birmingham, Alabama • Palo Alto, California • Sacramento, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

NCT07049055
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
El Segundo, California • Summit, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Terminated Phase 3 Interventional Results available

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

NCT03495921
View directory record Official record
Conditions
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
Interventions
Vigil, Irinotecan, Temozolomide
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Sep 30, 2026, 5:13 AM EDT
Not listed Phase 1Phase 2 Interventional

A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

NCT02990416
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
A-dmDT390-bisFv(UCHT1), Pembrolizumab, Ionizing Radiation
Biological · Radiation
Lead sponsor
Virogen Biotechnology Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 1 Interventional

Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma

NCT02574533
View directory record Official record
Conditions
Melanoma Recurrent, Malignant Melanoma, Melanoma
Interventions
Vigil, Pembrolizumab
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Abilene, Texas • Dallas, Texas • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Sep 30, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional Results available

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

NCT02855359
View directory record Official record
Conditions
Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
Interventions
denintuzumab mafodotin, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Sep 30, 2026, 5:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

NCT04193293
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Duvelisib, Pembrolizumab
Drug · Biological
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Sep 30, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional Results available

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

NCT05746481
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Tiragolumab, Atezolizumab, Pemetrexed, Carboplatin
Drug
Lead sponsor
Liza Villaruz, MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

NCT04639245
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Atezolizumab, Cyclophosphamide, Fludarabine, MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells, PD1 Inhibitor
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 3 Interventional Results available

Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone

NCT02562755
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Pexastimogene Devacirepvec (Pexa Vec), Sorafenib
Biological · Drug
Lead sponsor
SillaJen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
23
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 30, 2026, 5:13 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

NCT03792841
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Interventions
acapatamab, Pembrolizumab, Etanercept, Cytochrome P450 (CYP) Cocktail
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
13
States / cities
Campbell, California • Duarte, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Sep 30, 2026, 5:13 AM EDT
Completed Phase 2 Interventional

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

NCT04681131
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
CAB-AXL-ADC, PD-1 inhibitor
Biological
Lead sponsor
BioAtla, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
32
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 30, 2026, 5:13 AM EDT